These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16381666)

  • 1. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
    Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
    Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
    Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
    Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
    Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
    Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
    Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
    Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
    Frohna P; Lu J; Eppler S; Hamilton M; Wolf J; Rakhit A; Ling J; Kenkare-Mitra SR; Lum BL
    J Clin Pharmacol; 2006 Mar; 46(3):282-90. PubMed ID: 16490804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
    Ling J; Fettner S; Lum BL; Riek M; Rakhit A
    Anticancer Drugs; 2008 Feb; 19(2):209-16. PubMed ID: 18176118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.
    Vermeir M; Naessens I; Remmerie B; Mannens G; Hendrickx J; Sterkens P; Talluri K; Boom S; Eerdekens M; van Osselaer N; Cleton A
    Drug Metab Dispos; 2008 Apr; 36(4):769-79. PubMed ID: 18227146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, metabolism, and excretion of [
    Ye YE; Woodward CN; Narasimhan NI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
    Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
    Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
    Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
    Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.